The domestic selling price of amivantamab

Evantumumab (amivantamab) is one of the innovative bispecific antibody drugs introduced in China in recent years. It is used to treat non-small cell lung cancer patients with EGFR exon 20 insertion mutations. Since it was officially approved for marketing in mainland China in 2024, the drug has become the first biological agent to target this rare mutation type, filling the domestic treatment gap in this field of genotyping. At present, although evantumumab is already on the market in China, it has not yet been included in the national medical insurance directory, so patients mainly need to purchase the drug at their own expense.

According to the latest published data, the price of 350mg/bottle of Carestream in mainland China is about RMB 7,000, while the market price of the Hong Kong version or imported original drug is about RMB 8,000. There may be slight differences in different regions and channels. Some hospitals and pharmacies can provide direct supply services of imported drugs. Considering that it is a biological antibody preparation with high production costs and storage and transportation requirements, it is more expensive than small molecule targeted drugs.

In the international market, the pricing of evantumumab is generally high, and the cost of treatment per cycle in the U.S. market can reach thousands of dollars. Prices in the Chinese market are relatively low, mainly due to the government's promotion of localized registration of innovative drugs and the regional pricing strategies of pharmaceutical companies. With the increase in the number of drug users and changes in the competitive landscape, the industry generally expects that the price of this drug will be reduced through medical insurance negotiations or the introduction of generic drugs in the future.

It is worth noting that evantumumab has not yet been included in the national medical insurance catalog, but it has been included in the pilot scope of the tumor clinical drug catalog in many provinces and cities, and some hospitals can provide commercial insurance reimbursement or charity assistance plans. Such policy innovations have alleviated some of the financial burden on patients and accelerated the clinical popularization of drugs in the country.

Reference materials:https://www.rybrevant.com/